Our first half of 2024 report on longevity investment publishes today: the numbers, the deals and the outlook for the rest of the year.
The first half of 2024 marked a pivotal moment for longevity investments, showcasing a mix of resilience and challenges. According to our First Half Longevity Investment Report 2024, which Longevity.Technology Editor-in-Chief Phil Newman unveiled at Longevity Investors Conference today, the sector attracted $4.69 billion USD across Q1 and Q2.
While 2022 is still the year to beat, with $9.45 billion secured, 2024 is already outperforming 2023 which only managed $3.87 billion in financing – a stark reminder of the sector’s volatility. The current financing figures also highlight the untapped potential in emerging fields like longevity discovery platforms and neuropharma.
Key highlights
- Q1 2024 financing: $3.36 billion raised across 74 deals, with the US accounting for a whopping 92% of total financing. Longevity discovery platforms led the domain with $1.44 billion secured, driven by investments in companies like Denali Therapeutics.
- Q2 2024 financing: While the momentum slowed with $1.33 billion raised over 57 deals, neuropharma emerged as a dominant domain, securing $760 million, thanks to key players like Intra-Cellular Therapies.
This investment pattern underscores the growing interest in technologies that can extend healthspan – years lived in good health. Phil Newman, Editor-in-Chief of Longevity.Technology, noted that the demographic shift towards an aging population is catalyzing an urgent need for innovative health solutions. “Strategic investments now could shape not just the future of healthcare but the quality of life for billions,” he said. Newman discussed these issues as as part of his Investment metrics and trends in longevity presentation, in Gstaad.
Despite a notable decline from previous years, the concentration of funds in high-impact domains, such as rejuvenation, cellular reprogramming and neuropharma, indicates that investors remain cautiously optimistic. The increase from $3.87 billion in 2023 to $4.69 billion in the first half of 2024 highlights growth despite the global investment downturn, and also spotlights a focus on long-term growth areas like discovery platforms and genetic therapeutics.
Looking ahead
The First Half Longevity Investment Report 2024 reveals that, while financial volatility remains, the sector continues to hold promise for those willing to navigate its complexities. As society confronts the realities of aging, the surge in scientific advancements – from cellular reprogramming to longevity drugs – has never been more critical, and investors need to be aware of the regulatory landscape and the complex timelines involved. The second half of the year will be watched closely for further signals of recovery and expansion in the longevity market.
This year’s investment landscape demonstrates that the race for longevity breakthroughs is far from over, with strategic capital continuing to back revolutionary treatments for age-related diseases. Longevity science isn’t just about living longer – it is adopting a data-driven preventive approach centered on living healthier for longer.
Investors are encouraged to keep a close eye on emerging domains, particularly in cellular reprogramming and neuropharma, as they are poised to lead the next wave of breakthroughs in the longevity space.
Our report not only analyses longevity deals by stage, domain and location, it reflects on relevant investment issues such as the surge in popularity of semaglutides and the commensurate rise in counterfeit and illicit products. Our report aims to guide stakeholders in navigating the complexities of longevity investment, fostering sustainable progress in promoting extended healthspans for everyone.
